Stock Track | Hims & Hers Health Plummets 18.56% Pre-market as Novo Nordisk Terminates Weight Loss Drug Access

Stock Track

06-23

Shares of Hims & Hers Health Inc. (HIMS) plunged 18.56% in pre-market trading on Monday, following news that pharmaceutical giant Novo Nordisk has terminated its collaboration with the company. This unexpected development has significantly impacted investor sentiment towards the telehealth and wellness company.

Novo Nordisk announced that Hims & Hers Health will no longer have direct access to Wegovy®, a popular weight loss drug, via the NovoCare® Pharmacy. This termination of collaboration is likely to affect Hims & Hers Health's ability to offer this sought-after medication to its customers, potentially impacting its revenue stream and growth prospects in the weight management sector.

The sharp decline in Hims & Hers Health's stock price reflects investors' concerns about the company's future performance without access to Novo Nordisk's weight loss drug. As the healthcare sector continues to evolve, this development underscores the importance of strategic partnerships and product offerings in the competitive telehealth market.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1177566362"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177566362\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1177566362?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177566362","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plummets 18.56% Pre-market as Novo Nordisk Terminates Weight Loss Drug Access","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) plunged 18.56% in pre-market trading on Monday, following news that pharmaceutical giant Novo Nordisk has terminated its collaboration with the company. This unexpected development has significantly impacted investor sentiment towards the telehealth and wellness company.</p>\n\n<p>Novo Nordisk announced that Hims & Hers Health will no longer have direct access to Wegovy®, a popular weight loss drug, via the NovoCare® Pharmacy. This termination of collaboration is likely to affect Hims & Hers Health's ability to offer this sought-after medication to its customers, potentially impacting its revenue stream and growth prospects in the weight management sector.</p>\n\n<p>The sharp decline in Hims & Hers Health's stock price reflects investors' concerns about the company's future performance without access to Novo Nordisk's weight loss drug. As the healthcare sector continues to evolve, this development underscores the importance of strategic partnerships and product offerings in the competitive telehealth market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plummets 18.56% Pre-market as Novo Nordisk Terminates Weight Loss Drug Access</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plummets 18.56% Pre-market as Novo Nordisk Terminates Weight Loss Drug Access\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-06-23 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) plunged 18.56% in pre-market trading on Monday, following news that pharmaceutical giant Novo Nordisk has terminated its collaboration with the company. This unexpected development has significantly impacted investor sentiment towards the telehealth and wellness company.</p>\n\n<p>Novo Nordisk announced that Hims & Hers Health will no longer have direct access to Wegovy®, a popular weight loss drug, via the NovoCare® Pharmacy. This termination of collaboration is likely to affect Hims & Hers Health's ability to offer this sought-after medication to its customers, potentially impacting its revenue stream and growth prospects in the weight management sector.</p>\n\n<p>The sharp decline in Hims & Hers Health's stock price reflects investors' concerns about the company's future performance without access to Novo Nordisk's weight loss drug. As the healthcare sector continues to evolve, this development underscores the importance of strategic partnerships and product offerings in the competitive telehealth market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1177566362","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177566362","pubTimestamp":1750679322,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  plunged 18.56% in pre-market trading on Monday, following news that pharmaceutical giant Novo Nordisk has terminated its collaboration with the company. This unexpected development has significantly impacted investor sentiment towards the telehealth and wellness company.Novo Nordisk announced that Hims & Hers Health will no longer have direct access to Wegovy, a popular weight loss drug, via the NovoCare Pharmacy. This termination of collaboration is likely to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"由于诺和诺德终止减肥药准入，Hims&Hers Health盘前暴跌18.56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) plunged 18.56% in pre-market trading on Monday, following news that pharmaceutical giant Novo Nordisk has terminated its collaboration with the company. This unexpected development has significantly impacted investor sentiment towards the telehealth and wellness company.\nNovo Nordisk announced that Hims & Hers Health will no longer have direct access to Wegovy®, a popular weight loss drug, via the NovoCare® Pharmacy. This termination of collaboration is likely to affect Hims & Hers Health's ability to offer this sought-after medication to its customers, potentially impacting its revenue stream and growth prospects in the weight management sector.\nThe sharp decline in Hims & Hers Health's stock price reflects investors' concerns about the company's future performance without access to Novo Nordisk's weight loss drug. As the healthcare sector continues to evolve, this development underscores the importance of strategic partnerships and product offerings in the competitive telehealth market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}